Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 123 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Brentuximab Vedotin Clear all
Completed Phase 1 Interventional

Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation

NCT01700751
View directory record Official record
Conditions
Leukemia, Acute Myeloid, Leukemia, Lymphoblastic,Acute, Myelodysplastic Syndromes
Interventions
brentuximab vedotin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 25, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

NCT07013565
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions
Vinblastine (Velban), Brentuximab vedotin (Adcetris), Nivolumab (Opdivo)
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
43
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,

NCT03138499
View directory record Official record
Conditions
Hodgkin's Disease
Interventions
Nivolumab, Brentuximab vedotin
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
20
States / cities
Duarte, California • Long Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2024 · Synced Sep 25, 2026, 2:14 AM EDT
Withdrawn Phase 2 Interventional

Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas

NCT04334174
View directory record Official record
Conditions
T Cell Lymphoma
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Sep 25, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated With Brentuximab Vedotin or Checkpoint Inhibitors

NCT05039073
View directory record Official record
Conditions
Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Hematopoietic Cell Transplantation, Nivolumab, Quality-of-Life Assessment, Questionnaire Administration
Drug · Procedure · Biological + 1 more
Lead sponsor
Emory University
Other
Eligibility
12 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

NCT02408042
View directory record Official record
Conditions
Lymphoma, Hodgkin's Lymphoma, Non-hodgkin's Lymphoma
Interventions
Pembrolizumab, Etoposide, Ifosfamide, Mesna, Carboplatin, Brentuximab vedotin, Rituximab
Drug
Lead sponsor
Western Regional Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Goodyear, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 25, 2026, 2:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

NCT01703949
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Laboratory Biomarker Analysis, Nivolumab
Drug · Other · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 1 Interventional

Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies

NCT00430846
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic
Interventions
SGN-35
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Birmingham, Alabama • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

NCT01534078
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
4
States / cities
Tampa, Florida • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 25, 2026, 2:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma

NCT01920932
View directory record Official record
Conditions
Stage II Childhood Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
Interventions
brentuximab vedotin, etoposide, prednisone, doxorubicin, cyclophosphamide, Dacarbazine(R), filgrastim, quality of life assessment, radiation therapy
Drug · Other · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
6
States / cities
Palo Alto, California • Peoria, Illinois • Scarborough, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Terminated Phase 1 Interventional

Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

NCT01900496
View directory record Official record
Conditions
Lymphoma
Interventions
Brentuximab vedotin, Rituximab
Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
16 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 3 Interventional Results available

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

NCT01712490
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
83
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Active, not recruiting Phase 2 Interventional

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

NCT01352520
View directory record Official record
Conditions
CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Lymphomatoid Papulosis, Mycosis Fungoides, Skin Lymphoma, Cutaneous Lymphomas, Lymphoma, Hematologic Disorder
Interventions
SGN-35
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 2 Interventional

Brentuximab for Newly Diagnosed Hodgkin Disease

NCT02398240
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Doxorubicin, Vincristine, Rituximab
Drug
Lead sponsor
Mitchell Cairo
Other
Eligibility
1 Year to 29 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 25, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

NCT05253495
View directory record Official record
Conditions
Non-hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
DOC Group B, Pv-COMRAD 1 and 2 Group B, Pv-R-CYM 1 and 2 Group B, DOC Group C, MAD CPR 1 and 2, Pv-R CYVE 1 and 2, Pv-R CYVE-MTX 1 and 2, MAD CP, Pv-Cytarabine/etoposide, AD CP, Bv-AVD-R 1 and 2: COHORT IIa, Bv-NVD-R, Cycle 1-2, Bv-NVD-R, Cycle 1-4 SER, Bv-AVD-R, Bv-NVD-R, Cycle 1-4 RER, Bv-NAVD-R, Cycle 1-2, Involved Site Radiation Therapy
Drug · Radiation
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 39 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Birmingham, Alabama • Gainsville, Florida • Vallhala, New York
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma

NCT02505269
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Adriamycin, Dacarbazine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2020 · Synced Sep 25, 2026, 2:14 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

NCT03233347
View directory record Official record
Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Dacarbazine, Doxorubicin, Laboratory Biomarker Analysis, Nivolumab, Vinblastine
Drug · Other · Biological
Lead sponsor
Academic and Community Cancer Research United
Other
Eligibility
18 Years to 60 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Duarte, California • Rochester, Minnesota • Omaha, Nebraska + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

NCT02744612
View directory record Official record
Conditions
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Interventions
Brentuximab Vedotin, Ibrutinib
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
3
States / cities
Duarte, California • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Sep 25, 2026, 2:14 AM EDT
Recruiting Phase 2 Interventional

Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides

NCT05357794
View directory record Official record
Conditions
Mycosis Fungoides
Interventions
Brentuximab vedotin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Recruiting Phase 3 Interventional

Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

NCT04685616
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor
Radiation · Drug
Lead sponsor
University College, London
Other
Eligibility
16 Years to 69 Years
Enrollment
1,042 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
3
States / cities
Stanford, California • Miami, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

NCT01716806
View directory record Official record
Conditions
Hodgkin Disease, Peripheral T Cell Lymphoma
Interventions
brentuximab vedotin, bendamustine, dacarbazine, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 25, 2026, 2:14 AM EDT
Withdrawn Phase 2 Interventional

A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)

NCT04138875
View directory record Official record
Conditions
PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer, Plasmacytic Hyperplasia PTLD, Infectious Mononucleosis, Florid Follicular Hyperplasia PTLD, Polymorphic PTLD, Monomorphic PTLD, Classical Hodgkin Lymphoma Type PTLD
Interventions
Rituximab, Brentuximab Vedotin, Bendamustine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Sep 25, 2026, 2:14 AM EDT
Completed Phase 2 Interventional Results available

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

NCT01421667
View directory record Official record
Conditions
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
Interventions
brentuximab vedotin, rituximab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
6 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
33
States / cities
Birmingham, Alabama • Duarte, California • Oxnard, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2016 · Synced Sep 25, 2026, 2:14 AM EDT